Dr. Cassius Diego Belfonte, MD

Dr. Belfonte practices at Calvert Digestive Disease Associates, LLC in Prince Frederick, Maryland.

Dr. Belfonte's NPI, 1093978322, was assigned on July 7, 2008. Dr. Belfonte graduated from University of the West Indies Faculty of Medicine in 2005. Dr. Belfonte holds Maryland license D0076683.

Dr. Belfonte's primary practice is Calvert Digestive Disease Associates, LLC, at 110 Hospital Rd, Prince Frederick, MD 20678 in Calvert County. The practice phone is (410) 414-5309.

Dr. Belfonte's primary practice is Calvert Digestive Disease Associates, LLC in Prince Frederick, Maryland. Dr. Belfonte is also affiliated with CalvertHealth Medical Center. The medical group on file is Calvert Internal Medicine Group. Dmand AI also links Dr. Belfonte to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Belfonte practices, 3 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Belfonte's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Belfonte is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Belfonte's licenses on file in 2 states: Maryland and District of Columbia.

Dmand AI lists aneurysm, atrial fibrillation and flutter, cardiac catheterization, cardiomyopathy, cerebrovascular disease, chronic hypertension, coronary artery disease and heart blockage among the conditions Dr. Belfonte treats.

CMS data shows 7,231 Medicare services from Dr. Belfonte across 43 procedure codes in 2024, for 2,086 Medicare patients. Medicare paid $463,133 for them.

CMS counts 2,086 Medicare patients who saw Dr. Belfonte in 2024. The largest group is 75 to 84, with 785 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Belfonte's median patient age at 68, with 48% women.

In 2024, Dr. Belfonte wrote 4,068 Medicare Part D claims for 577 patients. 84% of them were for generic drugs. CMS names the drug for 3,777 of them, across 46 drugs with 11 or more claims each, at $800,259 in total drug cost. In 2023, CMS named 2,998 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Belfonte for performance year 2024, reported as part of a group. Dr. Belfonte accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Belfonte as offering telehealth.

Dmand AI links 4 papers to Dr. Belfonte, published from 2012 to 2015. 2012 was the busiest year, with 2. Dr. Belfonte's most frequent co-authors are Shodeinde Ariyo Coker, MD, Gail S. Kerr, MD and Nicole Anna Kieffer, DO.

CMS Open Payments shows 42 general payments to Dr. Belfonte from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Abbott Laboratories paid the most, $551.

Dmand AI lists 1 award for Dr. Belfonte, most recently Alpha Omega Alpha in 2011.

Dr. Belfonte graduated from University of the West Indies Faculty of Medicine in 2005. Dr. Belfonte is a member of AOA and ACC.

Dr. Belfonte is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.